IGC Pharma IncIGC
Price$0.27Intrinsic value$0.3633% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1M-3.9% YoYTTM through 30 Jun 2026
Net Income -$6.5MTTM through 30 Jun 2026
Free Cash Flow -$5.6MTTM through 30 Jun 2026

Margins

Current
Gross Margin17.3%
Operating Margin-775.4%
Net Margin-757.7%

Returns

-83.3%ROE
-50.3%ROA

Balance Sheet Health

Debt / Equity0.02x
Current Ratio1.32x
Net Debt$710K
Cash & Equivalents$331K

Quality Metrics

Altman Z-Score-14.97
FCF Margin-537.2%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $1.3M
Diluted EPS
'13'14'15'16'17'24'25
FY2025: $-0.09

Dividend

No dividend

Capital Allocation

Capex Intensity20.5%

Segment Performance

SegmentRevenueYoYOutlook
Life Sciences$317K-3.9%
View details

Focus remains on advancing the clinical pipeline, particularly the Phase 2 CALMA trial for lead asset IGC-AD1.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.